# ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer

_Oncology Research · Tian Zeng, Qingxi Luo, Li Yang et al. · 2026_

Canonical: https://diginpl.com/books/paper-or-2026-084046
Last updated: 2026-11-13

## Quick facts

- **Author:** Tian Zeng; Qingxi Luo; Li Yang; Feifan Hou; Yongqi Zhao; Xueru Liu; Ni Jiang; Juan Zou ([Crossref](https://doi.org/10.32604/or.2026.084046))
- **Published:** 2026 ([Crossref](https://doi.org/10.32604/or.2026.084046))
- **Publisher:** Tech Science Press ([Crossref](https://doi.org/10.32604/or.2026.084046))
- **Journal:** Oncology Research ([Crossref](https://doi.org/10.32604/or.2026.084046))
- **DOI:** 10.32604/or.2026.084046 ([Crossref](https://doi.org/10.32604/or.2026.084046))

## Questions

**Who wrote ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer?**  
ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer was written by Tian Zeng, Qingxi Luo, Li Yang, Feifan Hou.

**When was ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer first published?**  
ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer was first published in 2026.

## Sources

- [Publisher record (DOI, via Crossref)](https://doi.org/10.32604/or.2026.084046)

## Licence and attribution

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.084046.

## Cite this page

"ESM1 Enhances H3K9 Lactylation-Mediated GPRC5A Transcription to Induce mTOR Pathway Activation and Cisplatin Resistance in Ovarian Cancer". DigiNepal. Last updated 13 November 2026. https://diginpl.com/books/paper-or-2026-084046. Retrieved 14 November 2026.